Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Tuesday, 29 August 2017

The new anti-cancer drug, OMO-1, was given to the first cancer patient in the world last week in Oxford University’s Early Phase trials unit. Dr Sarah Blagden (Oxford’s ECMC lead and Director of the Early Phase Trials Unit) is Chief Investigator of this Phase I/II study of the combined c-MET/ OCT-1 inhibitor OMO-1 that was outlicenced from Janssen Pharmaceutica to be developed by the Belgian life science company OCTIMET Oncology NV.

Dr Blagden says “it is great to be able to offer our patients new therapies that could be the game-changers of the future.” The centre will be enrolling patients with advanced cancer into this study until Q3, 2018. 

Timothy Perera, CEO of OCTIMET says “We are pleased to reach this important milestone within 7 months of obtaining funding. We look forward to accelerating the development of this agent so that we can bring another personalised therapeutic option for patients in areas of unmet medical need.”

The next patient to enter the study is due to start treatment, also in Oxford, later this week.

Read on Oncology web site

Similar stories

Oxford spinout Optellum secures $14m funding to advance pioneering AI-powered lung cancer diagnosis technology

Optellum, a University of Oxford spinout that provides a breakthrough AI platform to diagnose and treat early-stage lung cancer, has raised $14 million in a Series A funding round.

New study shows higher rate of fractures in people with intellectual disability

In the most comprehensive study of its kind, researchers at the University of Oxford and Oxford Health NHS Foundation Trust found a substantially higher rate of fractures in people with intellectual disability compared with people of the same age and gender without an intellectual disability.

New evidence for how our brains handle surprise

A new study from the Bruno Group is challenging our perceptions of how the different regions of the cerebral cortex function. A group of ‘quiet’ cells in the somatosensory cortex that rarely respond to touch have been found to react mainly to surprising circumstances. The results suggest their function is not necessarily driven by touch, but may indicate an important and previously unidentified role across all the major cortices.

Language learning difficulties in children linked to brain differences

A new study using MRI has revealed structural brain changes in children with developmental language disorder (DLD), a common but under-recognised difficulty in language learning. Children with DLD aged 10-15 showed reduced levels of myelin in areas of the brain associated with speaking and listening to others, and areas involved in learning new skills. This finding is a significant advance in our understanding of DLD and these brain differences may explain the poorer language outcomes in this group.

New research reveals relationship between particular brain circuits and different aspects of mental wellbeing

Researchers at the University of Oxford have uncovered previously unknown details about how changes in the brain contribute to changes in wellbeing.